Bladder cancer remains one of the most common cancers in the United States and is a cause of substantial morbidity and mortality. The treatment of choice for superficial (non muscle-invasive) bladder cancer is cystoscopic resection followed by intra-vesical instillations of BCG. Although it is the most successful treatment for this indication, intravesical instillation of BCG is associated with a significant risk of cancer recurrence. We believe that some of the same mutations that cause bladder urothelial cells to become malignant also cause them to be susceptible to BCG. My work is focused on identifying these factors, which would allow us to predict an individual patient’s response to BCG, and to devise strategies to make treatment with BCG more effective.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gil Redelman-Sidi discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures